Lancet[journal] 检索结果

401. Hughes Stovin syndrome is not associated with pulmonary embolism.

作者: Nikolas Ruffer.;Martin Krusche.
来源: Lancet. 2025年405卷10476期379-380页

402. Endometriosis: an Australian perspective on encouraging change.

作者: Haddijatou Hughes.
来源: Lancet. 2025年405卷10476期378-379页

403. Future-proofing Europe and Central Asia: a renewed focus on child and adolescent health.

作者: Regina De Dominicis.;Hans Henri P Kluge.
来源: Lancet. 2025年405卷10476期377-378页

404. Case for a health equity framework in health technology assessment.

作者: Jonathan Pearson-Stuttard.;Bola Owolabi.
来源: Lancet. 2025年405卷10476期376-377页

405. Eliminating cervical cancer in the Tibetan Plateau.

作者: Le Dang.;Ma Mi.;Youlin Qiao.;Lan Zhu.
来源: Lancet. 2025年405卷10476期375-376页

406. Nepal set to launch historic HPV vaccination programme.

作者: Durga Neupane.;Lokesh Shekher Jaiswal.;Sefali Koirala.
来源: Lancet. 2025年405卷10476期375页

407. A doctor's lineage.

作者: Rachel Fleishman.
来源: Lancet. 2025年405卷10476期372-373页

408. Chloe Orkin: forefronting social justice in medicine.

作者: Aarathi Prasad.
来源: Lancet. 2025年405卷10476期370页

409. Offline: The journey towards equality.

作者: Richard Horton.
来源: Lancet. 2025年405卷10476期365页

410. Rising mpox trends in DR Congo: the neglected spread of an epidemic.

作者: Lorenzo Subissi.;Oriol Mitjà.
来源: Lancet. 2025年405卷10476期358-360页

411. Rethinking surveillance after breast cancer.

作者: Ritse M Mann.
来源: Lancet. 2025年405卷10476期356-358页

412. Cancer registries: the bedrock of global cancer care.

作者: The Lancet.
来源: Lancet. 2025年405卷10476期353页

413. Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study.

作者: Isabel Brosius.;Emmanuel Hasivirwe Vakaniaki.;Guy Mukari.;Papy Munganga.;Jean Claude Tshomba.;Elise De Vos.;Eugene Bangwen.;Yves Mujula.;Achilleas Tsoumanis.;Christophe Van Dijck.;Aimé Alengo.;Léandre Mutimbwa-Mambo.;Franklin Mweshi Kumbana.;Jenestin Babingwa Munga.;Divin Mazambi Mambo.;James Wakilongo Zangilwa.;Steeven Bilembo Kitwanda.;Sarah Houben.;Nicole A Hoff.;Jean-Claude Makangara-Cigolo.;Eddy Kinganda-Lusamaki.;Martine Peeters.;Anne W Rimoin.;Jason Kindrachuk.;Nicola Low.;Patrick D M C Katoto.;Espoir Bwenge Malembaka.;John H Amuasi.;Olivier Tshiani-Mbaya.;Dally Muamba Kambaji.;Richard Kojan.;Cris Kacita.;Daniel Mukadi-Bamuleka.;Steve Ahuka-Mundeke.;Koen Vercauteren.;Tony Wawina-Bokalanga.;Jean-Jacques Muyembe-Tamfum.;Sabin Sabiti Nundu.;Laurens Liesenborghs.;Placide Mbala-Kingebeni.
来源: Lancet. 2025年405卷10478期547-559页

Clade Ib, a new strain of clade I monkeypox virus, emerged in eastern DR Congo, sparking an international outbreak. Comprehensive studies are needed to assess its transmission dynamics and clinical presentation.

414. Challenges in containing the global spread of mpox clade Ib.

作者: Boghuma K Titanji.;Jason Zucker.
来源: Lancet. 2025年405卷10478期518-519页

415. Global health partnerships for a post-2030 agenda.

作者: Antoine de Bengy Puyvallée.;Sophie Harman.;Simon Rushton.;Katerini T Storeng.
来源: Lancet. 2025年405卷10477期514-516页

416. An imminent hazard: Dhaka's unbreathable air.

作者: Protyoi Chakraborty.
来源: Lancet. 2025年405卷10477期461-462页

417. US exit from WHO: it is about much more than WHO.

作者: Ilona Kickbusch.
来源: Lancet. 2025年405卷10477期444-446页

418. Announcing the Lancet Commission on US Societal Resilience in a Global Pandemic Age: Lessons for the Present from the Future.

作者: Eliah Aronoff-Spencer.;Richard M Carpiano.;Lara Vojnov.; .
来源: Lancet. 2025年405卷10477期448-450页

419. Dual checkpoint blockade for microsatellite instability-high colorectal cancer.

作者: S Daniel Haldar.;Scott Kopetz.
来源: Lancet. 2025年405卷10476期354-356页

420. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.

作者: Thierry André.;Elena Elez.;Heinz-Josef Lenz.;Lars Henrik Jensen.;Yann Touchefeu.;Eric Van Cutsem.;Rocio Garcia-Carbonero.;David Tougeron.;Guillermo Ariel Mendez.;Michael Schenker.;Christelle de la Fouchardiere.;Maria Luisa Limon.;Takayuki Yoshino.;Jin Li.;Jose Luis Manzano Mozo.;Laetitia Dahan.;Giampaolo Tortora.;Myriam Chalabi.;Eray Goekkurt.;Maria Ignez Braghiroli.;Rohit Joshi.;Timucin Cil.;Francine Aubin.;Elvis Cela.;Tian Chen.;Ming Lei.;Lixian Jin.;Steven I Blum.;Sara Lonardi.
来源: Lancet. 2025年405卷10476期383-395页

CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab compared with nivolumab alone, regardless of previous systemic treatment for metastatic disease. In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis for the other primary endpoint of progression-free survival for nivolumab plus ipilimumab versus nivolumab across all treatment lines.

结果排序

文献格式

出版时间

出版类型

出版语言